环丙基(吡啶-2-基)甲胺盐酸盐 | 478263-93-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 环丙基(吡啶-2-基)甲胺盐酸盐
• 英文名称: cyclopropyl(pyridin-2-yl)methanamine dihydrochloride
• 英文别名: Cyclopropyl(pyridin-2-YL)methanamine hcl；cyclopropyl(pyridin-2-yl)methanamine;hydrochloride
• CAS: 478263-93-3
• 化学式: C₉H₁₂N₂*2ClH
• 分子量: 221.13
• InChiKey: UCOQXOUIBFTFOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  环丙基(吡啶-2-基)甲胺盐酸盐 、 三氟乙酸酐 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.58h， 以76%的产率得到1-cyclopropyl-3-(trifluoromethyl)imidazo[1,5-a]pyridine
  参考文献：
  名称：

  使用TFAA和三氟乙酰胺作为CF 3-试剂可扩展合成三氟甲基化的咪唑基氮杂杂环

  摘要：

  提出了使用TFAA作为三氟甲基化试剂从杂环苄胺可扩展合成三氟甲基化的咪唑并稠合的N-杂环。反应通过中间体苄基N-三氟乙酰胺进行，然后脱水环化为产物。为了进一步拓宽范围和实用性，开发了通过三氟乙酰胺与苄基（伪）卤化物的烷基化制备苄基N-三氟乙酰胺的新方法。两种方法都在温和的条件下进行，并且它们的共生提供了广泛的新型CF 3-杂环的途径。

  DOI：

  10.1021/acs.orglett.7b03291

文献信息

• Anthranilamides and methods of their use
  申请人：——

  公开号：US20030187033A1

  公开（公告）日：2003-10-02

  The present invention is related to anthranilamides of formula I, 1 in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及具有式I的蒽酰胺，其中R(1)至R(7)具有本文中指示的含义，其制备方法，它们作为药物的用途，以及含有它们的药物制剂。这些化合物作用于Kv1.5钾通道，抑制一种被称为人类心房中超快速激活延迟整流器的钾电流。因此，这些化合物适用于作为新型抗心律失常药物，用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
  申请人：——

  公开号：US20030114499A1

  公开（公告）日：2003-06-19

  This invention encompasses anthranilamides with heteroarylsulfonyl side chain, process for their preparation, their use as medicament or diagnostic aid, and pharmaceutical preparations containing them. Compounds of formula I, 1 in which R1 to R7 have the meanings stated in the claims, act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. They are therefore suitable as novel antiarrhythmic ingredients, such as for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutter.

  这项发明涵盖了具有杂环磺酰基侧链的蒽酰胺，其制备方法，它们作为药物或诊断辅助剂的用途，以及含有它们的制药制剂。具有式I的化合物，在其中R1至R7具有权利要求中所述的含义，作用于Kv1.5钾通道，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，它们适用作为新型抗心律失常成分，例如用于治疗和预防心房心律失常，如心房颤动（AF）或心房扑动。
• ANTHRANILAMIDES AND METHODS OF THEIR USE
  申请人：Brendel Joachim

  公开号：US20070117807A1

  公开（公告）日：2007-05-24

  The present invention is related to a process for preparing anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及一种制备式I的蒽酰胺的方法，其中R（1）至R（7）具有本文中所示的含义，其制备方法，作为药物的使用以及含有它们的制药制剂。该化合物对Kv1.5钾通道产生作用，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，该化合物适用于作为新型抗心律失常剂用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：University Health Network

  公开号：US20140371202A1

  公开（公告）日：2014-12-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I′) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供由结构式（I）或（I'）所代表的吲唑化合物或其药学上可接受的盐。还描述了制备药物组合物和使用方法，作为蛋白激酶抑制剂，例如TTK蛋白激酶，极化样激酶4（PLK4）和极化激酶，对乳腺癌细胞，结肠癌细胞和卵巢癌细胞具有抗癌活性。
• US6903216B2
  申请人：——

  公开号：US6903216B2

  公开（公告）日：2005-06-07